TransMedics Group, Inc.
Rank #282HypergrowthTMDX · Nasdaq · Healthcare
TransMedics Group, Inc. (TMDX) — Rank #282 by gross profitability (GP/assets 0.25) · ROE 36.7% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001756262 · all metrics point-in-time as of the filing date.
About
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Show moreShow less
The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- MA
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- transmedics.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-24 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-27 | 2022-12-31filed 2023-02-27 |
|---|---|---|---|---|
| Revenue | 605.5 | 441.5 | 241.6 | 93.5 |
| Revenue growth (YoY) | 37.1% | 82.7% | 158.5% | 208.8% |
| Cost of revenue | 242.7 | 179.5 | 87.5 | 28.2 |
| Gross profit | 362.8 | 262.1 | 154.1 | 65.3 |
| Gross margin | 59.9% | 59.4% | 63.8% | 69.8% |
| Selling, general & administrative | 185.2 | 168.6 | 119.6 | 69.9 |
| Research & development | 69.1 | 56.0 | 36.1 | 26.8 |
| Operating income | 108.6 | 37.5 | (28.7) | (31.4) |
| Operating margin | 17.9% | 8.5% | -11.9% | -33.6% |
| Interest expense | — | — | 10.8 | 3.7 |
| Pre-tax income | 107.5 | 35.8 | (26.7) | (36.2) |
| Income tax expense | (82.8) | 0.3 | (1.7) | — |
| Net income | 190.3 | 35.5 | (25.0) | (36.2) |
| Net margin | 31.4% | 8.0% | -10.4% | -38.8% |
| EPS (basic) | $5.60 | $1.07 | -$0.77 | -$1.23 |
| EPS (diluted) | $4.87 | $1.01 | -$0.77 | -$1.23 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?